Where GenAI Fits Inside Clinical Trial Submissions in 2026

FDA guidance changed the conversation around GenAI in submissions. The harder question in 2026 is how sponsors maintain traceability, authorship, and defensible workflows under regulatory scrutiny.

By the time the U.S. Food and Drug Administration (FDA) released its January 2025 draft guidance on AI use in regulatory decision-making for drugs and biologics, generative AI had already entered regulatory operations in quieter, less formal ways. Medical writers were experimenting with draft summaries, regulatory teams were testing terminology harmonization across modules, and some organizations had started using GenAI-assisted quality checks for references, formatting consistency, and source reconciliation.   The guidance did not suddenly introduce AI into clinical submissions. What it did was change the level of scrutiny surrounding how AI-assisted work is documented, reviewed, and defended during regulatory review.  That distinction matters more than many discussions around “AI in pharma” currently acknowledge. A clinical submission is not a single document assembled by one team working in isolation. An eCTD submission may involve regulatory affairs groups, CROs, medical writers, biostatistics teams, pharmacovigilance specialists, clinical operations, quality functions, and external vendors working across different systems and timelines. Some sections are administrative; others directly influence safety interpretation, efficacy narratives, or regulatory conclusions.  GenAI does not interact with all of those sections equally.  The operational question facing sponsors in 2026 is becoming narrower and more practical than the broader public discussion around AI adoption. Companies are no longer evaluating whether generative AI can accelerate portions of submission work because many already know that it can. The harder problem is determining where acceleration remains operationally defensible once documentation standards, inspection readiness, and human accountability enter the picture. 

The Submission Workflow Has Become More Visible to Regulators 

The FDA’s draft guidance focuses heavily on credibility assessment, lifecycle management, risk evaluation, and documentation expectations surrounding AI-supported regulatory decision-making.   At roughly the same time, the European Medicines Agency continued expanding its attention on traceability, reproducibility, and governance expectations surrounding AI systems used across the medicinal product lifecycle.   However, neither agency established a simple approved-versus-prohibited list for GenAI usage inside submissions. The regulatory posture is more procedural than categorical. Reviewers increasingly expect sponsors to explain: 

• Where AI-assisted workflows were used 

• What role the system played 

• How outputs were reviewed 

• How changes were tracked 

• How source traceability was maintained 

That changes the operational burden around submissions in subtle ways.  Historically, many regulatory processes focused primarily on the integrity of the final artifact handed to the agency. AI-assisted workflows introduce more attention on the chain surrounding the artifact itself: prompts, review processes, validation logic, source linkage, workflow controls, and version history.  The closer an AI system moves toward interpretive or judgment-heavy content, the more sensitive that chain becomes. 

Different Sections of the eCTD Carry Different Levels of Exposure 

One of the more misleading assumptions surrounding GenAI in regulatory operations is the idea that “AI in submissions” represents a single use case.  It does not.  An Electronic Common Technical Document (eCTD) submission contains sections with very different operational and regulatory characteristics. Administrative summaries, cross-reference checks, terminology alignment, and structured formatting tasks carry a different level of exposure than efficacy conclusions, statistical interpretation, or safety analysis.  That distinction is beginning to shape how sponsors structure internal AI policies. 

Where GenAI Workflows Currently Sit Across Submission Environments 

SUBMISSION ACTIVITY	OPERATIONAL SENSITIVITY	TYPICAL GOVERNANCE EXPECTATION
Terminology harmonization	Lower	Human verification and audit logging
Cross-reference and QC checks	Lower	Workflow traceability and reviewer sign-off
Administrative drafting support	Lower	Source validation and documented review
Clinical narrative scaffolding	Moderate	Structured source linkage and accountable medical review
CSR drafting assistance	Moderate	Human authorship, validation evidence, and workflow controls
Statistical interpretation	High	Traceable code, validated datasets, direct expert oversight
Safety or efficacy conclusions	High	Human-led authorship and regulatory accountability

  Lower-risk uses currently receiving broader acceptance across the industry include: 

• document quality checks 

• consistency validation 

• metadata organization 

• terminology harmonization 

• structured summarization 

• limited drafting support for low-decision-impact content with full human review 

The closer GenAI moves toward clinical interpretation, however, the less comfortable organizations become with fully automated drafting behavior.  Patient narratives illustrate the issue clearly. A narrative generated from validated structured datasets, reviewed by accountable medical writers, and linked cleanly back to source records sits inside a very different operational category than unconstrained narrative generation from fragmented or poorly governed data sources.  This distinction affects inspection readiness.  Sponsors increasingly need to explain how specific submission content was produced, what controls existed around the workflow, and whether reviewers can reconstruct the chain between the source material and the final language submitted to regulators. 

Regulatory Teams Are Discovering That Informal AI Usage Is Difficult to Audit Later 

Large pharmaceutical companies including Pfizer, Roche, and Moderna have publicly discussed broader investments in AI-enabled operations, research, and documentation environments during the past two years.   At the operational level, however, adoption patterns remain uneven across the industry.  Many medical-writing and regulatory teams are still operating inside environments where unofficial AI-assisted drafting behavior exists alongside formal governance programs. Teams under submission pressure may use public or semi-governed systems for first-pass summaries, editing support, formatting assistance, or draft refinement long before organization-wide validation frameworks fully mature.  That creates a practical problem during audit, inspection, or internal review. Once AI-assisted content enters a workflow without documented controls, reconstructing the history around that content becomes significantly harder. Organizations may struggle to determine: 

• Which system generated the output 

• Whether prompts were retained 

• Whether source documents remained validated 

• How reviewers modified the content 

• Whether model behavior changed during the submission lifecycle 

None of these concerns imply widespread misconduct or reckless adoption across the industry. Most emerge from ordinary operational pressure inside highly compressed submission timelines. Clinical study reports still require extensive drafting and reconciliation work, safety narratives continue to remain labor-intensive, and submission teams still manage large documentation volumes under strict review deadlines.  GenAI entered those workflows because the workload already existed. 

The Operational Burden Is Shifting Toward Traceability 

One of the more significant shifts happening inside regulatory operations is that generating text is becoming easier much faster than documenting the conditions under which the text was produced. This shift affects validation strategy directly.  Under frameworks such as 21 CFR Part 11 and EU Annex 11, sponsors already maintain expectations around auditability, electronic records, access control, validation discipline, and system integrity. Generative AI complicates those expectations because the workflow surrounding the model becomes part of the operational environment regulators may eventually examine.  Organizations now have to think beyond model performance alone: 

• Which prompts are approved? 

• Which datasets are permitted? 

• How are outputs reviewed? 

• What evidence demonstrates human verification? 

• What happens when a model version changes mid-program? 

• How is workflow drift detected? 

Several regulatory technology vendors have started positioning their offerings around governance and controlled workflow orchestration rather than autonomous regulatory writing. Veeva Systems has emphasized controlled content operations and governed data environments across regulated workflows, while IQVIA has focused heavily on traceability and operational governance surrounding AI-supported life sciences systems.   That positioning reflects where much of the industry attention is now moving: workflow control rather than unrestricted generation. 

What More Mature Submission Programs Are Starting to Look Like 

Organizations approaching GenAI cautiously inside regulatory operations are increasingly mapping AI usage policies to section levels rather than treating them as universal submission-wide permissions. Sponsors define where AI-assisted drafting is acceptable, where additional review controls apply, and where full human authorship remains mandatory.  Traceability is also becoming continuous instead of retrospective. Submission environments are starting to retain: 

• Workflow evidence 

• Source lineage 

• Reviewer attribution 

• Version history 

• Validation records 

• Documented change-control procedures throughout the drafting lifecycle itself 

Human accountability remains highly visible throughout the process. Even when AI-assisted systems contribute to portions of drafting or review, sponsors still maintain named human ownership around the final submission content and the regulatory conclusions attached to it.  The operational logic behind that structure is straightforward. Regulatory agencies review submissions in contexts where decisions affect patient safety, product approval, labeling, risk evaluation, and post-market obligations. Sponsors therefore need workflows that remain explainable under inspection conditions months or years after submission activity occurred. This requirement changes how AI systems can realistically be integrated into regulated documentation environments. 

The Harder Long-Term Question May Center on Authorship Rather Than Automation 

Most discussions around generative AI in life sciences still focus on speed: 

• Faster drafting 

• Faster submissions 

• Faster review cycles 

• Faster reconciliation 

Those gains are real in certain parts of the workflow. But the more consequential shift may emerge somewhere else entirely.  Clinical submissions historically carried relatively clear relationships between authorship, review responsibility, and source interpretation. Generative systems introduce additional layers between those activities. Content may now pass through prompts, orchestration systems, structured datasets, retrieval pipelines, review interfaces, and multiple human reviewers before becoming part of a final submission package.  The operational challenge is no longer limited to whether AI can generate language that sounds credible. The challenge is maintaining a defensible chain around how regulated content moved from source material to final submission under conditions that remain explainable long after the workflow itself has ended.  That pressure is beginning to reshape regulatory operations more than many broader discussions around “AI transformation” suggest.  Near the end of that process, companies like Fulcrum Digital sit increasingly close to the infrastructure and workflow-governance layer surrounding regulated AI environments: operational traceability, governed orchestration, auditability controls, and production systems designed to remain defensible under live regulatory conditions. For teams thinking through this next layer of AI adoption, our experts can help frame the path forward.  Book a call today. 

 

Key Takeaways 

• FDA guidance on GenAI clinical trial submissions is shifting regulatory attention toward workflow traceability, validation, and human accountability. 

• Different eCTD sections carry different levels of operational and regulatory risk for GenAI-assisted drafting and review. 

• GenAI in regulatory writing is becoming easier to deploy than to document, audit, and defend during inspection. 

• Pharmaceutical companies are increasingly treating AI governance as a workflow problem rather than only a model-validation problem. 

• AI-assisted clinical submission workflows now require stronger controls around prompts, source linkage, reviewer attribution, and version history. 

Frequently Asked Questions 

Does the FDA allow GenAI in clinical trial submissions in 2026? 

The FDA has not issued blanket approval for all GenAI usage inside regulatory submissions. Its January 2025 draft guidance established a risk-based framework surrounding credibility, validation, lifecycle management, and documentation expectations for AI-supported regulatory processes. Lower-risk operational tasks such as formatting support, terminology harmonization, and document-quality workflows appear increasingly acceptable when sponsors maintain strong review and traceability controls. Scientific interpretation and regulatory judgment still require direct human accountability. 

Which parts of an eCTD submission currently carry lower operational risk for GenAI assistance? 

Administrative content, structured summarization, cross-reference checks, formatting validation, metadata organization, and terminology consistency are generally viewed as lower-risk operational uses for GenAI systems. Some sponsors are also exploring tightly governed drafting support for clinical narratives and portions of clinical study reports where validated source linkage and human review remain fully documented. Risk increases substantially when AI systems move closer to efficacy interpretation or safety conclusions. 

Why are pharmaceutical companies concerned about undocumented AI usage in regulatory workflows? 

Undocumented AI-assisted drafting creates traceability problems during inspection or internal review. Organizations may struggle to reconstruct which system generated the content, how reviewers modified outputs, whether validated datasets were used, or whether workflow controls changed during the submission lifecycle. Most concerns stem from operational inconsistency rather than deliberate misuse. Submission timelines remain compressed, and teams often experiment informally before enterprise governance structures fully mature. 

Does 21 CFR Part 11 apply to AI-assisted submission workflows? 

It can. If AI-assisted systems contribute to regulated electronic records or submission workflows governed under 21 CFR Part 11, sponsors may need to maintain auditability, validation controls, access restrictions, electronic signatures, and documented workflow integrity across the surrounding operational environment. Regulators increasingly examine the workflow around the model rather than evaluating model performance in isolation. 

How does Fulcrum Digital approach governed AI workflows in regulated industries? 

Fulcrum Digital focuses on the operational systems surrounding enterprise AI deployments in regulated environments: workflow traceability, governed orchestration, auditability controls, validation discipline, and production infrastructure designed for environments where regulatory accountability remains attached to human decision-making.